Who we are?
VACCELERATE is a clinical research network for the coordination & conduct of COVID-19 vaccine trials. The network is comprised of academic institutions from all over Europe: The consortium is led by the University of Cologne, Germany, and currently includes 26 national partners in 16 EU-member states & 5 countries associated to the EU Horizon 2020 research programme.
VACCELERATE is funded by the European Commission's activities for future pandemic preparedness, the "HERA Incubator", an instrument that was created in analogy to United States' BARDA.
What we do!
VACCELERATE offers expertise, services, resources and solutions to speed up existing and upcoming development programmes and market authorisation for new vaccines and vaccination strategies. The network serves as a single entry-point for all stakeholders in COVID-19 vaccine development (pharma, academia, European Commission, EMA, ECDC, national health authorities and others) for phase 2 & 3 trials in Europe. The network will address any research question of interest, such as vaccine efficacy in virus variants, trials in children, pregnant women, immuno-compromised patients, trials on combination of different vaccines etc. The establishment of a European volunteer registry for vaccine trials provides fast & efficient recruitment of trial participants (>20,500 volunteers in Germany alone, expansion to more countries ongoing).
VACCELERATE conducts capacity mapping of new clinical trial sites & laboratories with standardised methods and protocols, and provides standardised educational measures, training and quality management for harmonised vaccine trials. It already holds information on 226 clinical trial sites in 32 European countries (Link: EUVAP). Harmonisation of data acquisition across all network sites enables open data exchange for valid data analysis.